Latest News
-
CARBOGEN AMCIS announces successful ANVISA audit of its facility in China
BUBENDORF, Switzerland (19 March 2024) – Switzerland-based CARBOGEN AMCIS, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, announces the successful completion of its first Brazilian Regulatory Authority Agency (ANVISA) routine inspection of its facility in Shanghai. -
CARBOGEN AMCIS Manchester wins prestigious Chemical Industry Award for world-class manufacturing performance
Manchester, UK (20 June 2023) – CARBOGEN AMCIS Manchester, a member of the Switzerland-based CARBOGEN AMCIS Group, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, won the Manufacturing and Resource Efficiency Award at the prestigious Chemistry Industry Awards last week. -
CARBOGEN AMCIS announces successful FDA and Swissmedic inspections of its facilities in Switzerland
BUBENDORF, Switzerland (02 June 2023) – Switzerland-based CARBOGEN AMCIS, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, announces the completion of a U.S. Food and Drug Administration (FDA) inspection at its headquarters in Bubendorf, Switzerland and a Swissmedic routine inspection at Bubendorf, Aarau and Neuland, Switzerland. -
CARBOGEN AMCIS opens new state-of-the-art facility dedicated to sterile liquid drug product manufacturing in France
Bubendorf, Switzerland (3 February 2023) – Switzerland-based CARBOGEN AMCIS, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, has opened a state-of-the-art facility in Saint-Beauzire, France. -
CARBOGEN AMCIS Announces a Successful FDA Inspection of its Headquarters Site in Bubendorf, Switzerland
BUBENDORF, Switzerland (October 11th, 2017) — Switzerland-based CARBOGEN AMCIS AG, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, announced today that its Bubendorf, Switzerland API manufacturing site has successfully completed a routine U.S. Food and Drug Administration (FDA) inspection. -
CARBOGEN AMCIS Sites at Bubendorf, Aarau and Neuland in Switzerland Successfully Pass Swissmedic Inspection
BUBENDORF, Switzerland (July 21st, 2017) — Switzerland-based CARBOGEN AMCIS AG, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, announced the renewal of cGMP certificates, and the successful completion of Swissmedic inspections at three of its sites. -
Dishman Celebrates a Decade of Success Since Acquisition of CARBOGEN AMCIS
AHMEDABAD, INDIA, August 11, 2016 – Dishman Pharmaceuticals and Chemicals Ltd (DPCL), leading outsourcing partner for the global pharmaceutical industry, today marked the 10-year anniversary of its acquisition of CARBOGEN AMCIS. A significant milestone of growth and development of Indian-Swiss business relations. -
CARBOGEN AMCIS Sites at Aarau and Neuland in Switzerland Successfully Pass FDA Inspection
BUBENDORF, Switzerland (July 13th, 2016) — Switzerland-based CARBOGEN AMCIS AG, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, announced, after reception of the Establishment Inspection Report (EIR), that two of its Swiss sites have successfully completed a U.S. Food and Drug Administration (FDA) inspection. -
CARBOGEN AMCIS Expands Operations in Bubendorf
BUBENDORF, Switzerland (May 31st, 2016) — CARBOGEN AMCIS, the Swiss-based company offering process development and manufacturing of Active Pharmaceutical Ingredient (API) to the pharmaceutical industry, has announced the extension of its operations in Bubendorf.
Upcoming Events
Search
